Profitable Growth - in full compliance!

The overall business focus of SOLVING is the pragmatic and hands-on support of our customers in systematically identifying and exploiting growth potentials.


We have developed a very specific approach that leads to a rapid time to benefit, tangible and lasting top-and bottom-line impact.


All enabling areas will be aligned with the critical growth factors in order to  exploit the defined growth-areas and growth sources.


Our international and operative experience assures that the growth initiatives can and will be implemented and are easily accepted in the organization.

PharmaTimes: News RSS

New prescriptions of Allergan’s Esyma on hold (Di, 20 Feb 2018)
Doctors are not to prescribe Allergan’s Esmya for uterine fibroids in the UK while European regulators carry out a safety review of the drug.
>> mehr lesen

Shire, Microsoft and EURODIS form rare diseases alliance (Di, 20 Feb 2018)
Shire has teamed up with Microsoft and EURORDIS-Rare Diseases Europe in a strategic alliance aiming to tackle the diagnostic challenge for patients living with a rare disease.
>> mehr lesen

SMC approves NHS funding for UCB’s Vimpat in children (Di, 20 Feb 2018)
Children living in Scotland with epilepsy will get NHS-funded treatment with UCB’s Vimpat following a green light from cost regulators.
>> mehr lesen